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Abstract
Despite recent improvement in adjuvant therapies, triple-negative, and ER+ subtypes of breast cancer (BC) with metastatic
potentials remain the leading cause of BC-related deaths. We investigated the role of phosphatidylinositol-4-phosphate 5-
kinase alpha (PIP5Kα), a key upstream factor of PI3K/AKT, and the therapeutic effect of PIP5Kα inhibitor on subtypes of
BC. The clinical importance of PIP5K1α and its association with survivals were analyzed using three BC cohorts from
Nottingham (n= 913), KM plotter (n= 112) and TCGA (n= 817). Targeted overexpression or knockdown of PIP5K1α
were introduced into BC cell lines. The effects of PIP5K1α and its inhibitor on growth and invasion of BC were confirmed
by using in vitro assays including proliferation, migration, apoptosis and luciferase reporter assays and in vivo xenograft
mouse models. All statistical tests were two-sided. PIP5K1α was associated with poor patient outcome in triple-negative BC
(for PIP5K1α protein, p= 0.011 and for mRNA expression, p= 0.028, log-rank test). 29% of triple-negative BC had
PIP5K1A gene amplification. Elevated level of PIP5K1α increased expression of pSer-473 AKT (p < 0.001) and
invasiveness of triple-negative MDA-MB-231 cells (p < 0.001). Conversely, inhibition of PIP5K1α using its inhibitor ISA-
2011B, or via knockdown suppressed growth and invasiveness of MDA-MB-231 xenografts (mean vehicle-treated controls
= 2160 mm3, and mean ISA-2011B-treated= 600 mm3, p < 0.001). ISA-2011B-treatment reduced expression of pSer-473
AKT (p < 0.001) and its downstream effectors including cyclin D1, VEGF and its receptors, VEGFR1 and VEGFR2 (p <
0.001) in xenograft tumors. In ER+ cancer cells, PIP5K1α acted on pSer-473 AKT, and was in complexes with VEGFR2,
serving as co-factor of ER-alpha to regulate activities of target genes including cyclin D1 and CDK1. Our study suggests that
our developed PIP5K1α inhibitor has a great potential on refining targeted therapeutics for treatment of triple-negative and
ER+ BC with abnormal PI3K/AKT pathways.
Introduction
Breast cancer is a disease of heterogeneity at clinical,
morphological, molecular, and genomic levels [1]. Patients
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with luminal breast cancers that are hormone receptor
positive (estrogen receptor (ER+) and progesterone receptor
(PR+)), may suffer cancer recurrence, which often metas-
tasize to bone but respond well to endocrine therapies [2, 3].
Triple-negative or basal-like breast cancers, which are
defined as breast cancer without expression of ER, PR and
human epidermal growth factor receptor 2 (HER2), are
found to be associated with shorter time to recurrence and
higher metastatic potentials [4–6]. They do not respond to
endocrine therapies, thereby represent a major clinical
challenge [7, 8].
A complex network of signaling pathways may con-
tribute to distant metastasis, which is the major cause of
death of breast cancer [1, 9, 10]. The pathways often
converge at the phosphatidylinositol 3-kinase (PI3K)/AKT
pathway, which is a central player that controls cell cycle,
survival, metabolism, motility, and genomic instability [11].
Indeed, PIK3CA mutations or PTEN loss resulting in con-
stitutively activation of PI3K/AKT are frequently observed
in ER+ luminal subtype and in triple-negative, basal-like
breast cancers as well [7]. Thus, there is an intense interest
in identifying novel approaches to inhibit PI3K/AKT.
Phosphatidylinositol 4-phosphate 5-kinase alpha
(PIP5K1α) is responsible for the synthesis of PtdIns-4,5-P2
(PIP2), which is in turn used by PI3K to produce PtdIns-
3,4,5-P3 (PIP3). PIP3 plays an important role in activation
of AKT [12, 13], therefore, PIP5K1α acts on upstream of
the PI3K/AKT/PTEN pathways and can regulate cell
Fig. 1 Expression of PIP5K1α
protein and mRNA correlates
with patient outcome in in triple-
negative subtypes of breast
cancer. a Immunohistochemical
analysis of TMAs containing
primary tumor tissues from 913
breast cancer patients using
antibody against PIP5K1α.
Representative
microphotographs showing
PIP5K1α expression and
subcellular localization in
various types of breast cancer
tissues. b, c Kaplan–Meier
survival analysis based on
disease-free (b) or distant
metastasis-free (c) shows the
difference between patients with
low or high expression of
PIP5K1α in a triple-negative
breast cancer patient cohort. d
Kaplan–Meier survival analysis
shows the differences between
patients with high or low
PIP5K1A in Lumina A breast
cancer patient cohort. e Kaplan-
Meier survival analysis shows
the differences between patients
with high or low PIP5K1A/
AKT1 mRNA levels in a triple-
negative breast cancer patient
cohort. Differences in disease-
free or metastasis-free survivals
between two groups were
calculated using the log-rank
test. P values are indicated. f
Alterations in PIP5K1A in 20%
(n= 164) of unselected cases of
breast cancer (n= 817 cases),
and in 17% (n= 102) of ER+
subtype (n= 594), and in 24%
(n= 29) of HER-2 positive
subtype (n= 120) and in 29%
(n= 24) of triple-negative
subtypes (n= 82)
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proliferation, apoptosis, and migration. Overexpression of
PIP5K1α has been detected in MDA-MB-231 cell line,
showing its involvement in breast cancer [14]. Previously
we reported that a selective PIP5K1α inhibitor, ISA-2011B,
blocked the PI3K/AKT pathway by decreasing AKT
phosphorylation at Serine 473 (pAKT S473), leading to
reduced growth of aggressive prostate tumors in a xenograft
mouse model [15, 16]. Therefore, it is necessary to inves-
tigate the therapeutic potential of ISA-2011B on inhibiting
the PI3K/AKT pathway in breast cancer as a targeted and
possibly more effective therapy for patients with activated
PI3K/AKT [17–21].
In this paper, we studied the involvement of PIP5K1α
with the PI3K/AKT pathway in triple-negative and luminal
ER+ breast cancers. We aimed at exploring the utility of
ISA-2011B for treatment of metastatic breast cancer models
by blocking constitutively activated PI3K/AKT pathway in
preclinical settings. Our results suggest a role of PIP5K1α
and ISA–2011B in targeted treatment of metastatic breast
cancer.
Results
Expression of PIP5K1α in specimens of primary
breast cancer patients
We examined PIP5K1α expression using tissue microarrays
(TMAs) consisting of molecular subtypes including luminal
subtypes and basal-like classes [22]. Expression of
PIP5K1α protein was detected in breast cancer tissues of
various subtypes (Fig. 1a). In the luminal subtype, higher
level of PIP5K1α was shown to be associated with high-
grade cancers and cancers with poor prognosis, respectively
(p= 0.031 and p= 0.004) (n= 606) (Tables 1 and 2), and
such association is similarly observed in the unselected
cases (Table 1). Interestingly, in the triple-negative subtype
(n= 163), more postmenopausal patients had high
PIP5K1α expression than premenopausal patients (p=
0.013). Overexpression of PIP5K1α was frequently asso-
ciated with tumors at larger size (p= 0.017) and PIK3CA
mutations (p= 0.037) (Table 3). Further, patients with
higher PIP5K1α expression (n= 91) suffered poorer
disease-free survival (DFS) as compared to the lower
expression group (n= 72) (p= 0.011) (Fig. 1b). Patients
with higher level of PIP5K1α (n= 85) also suffered poorer
metastatic-free survival as compared with those with lower
levels (n= 68), and had an increased risk of distant
metastasis (HR= 2.138, 95% CI: 1.14-4.009, p= 0.015)
(Fig. 1c). We then examined PIP5K1A mRNA expression
in luminal and triple-negative breast cancer subtypes by
using patient cohorts from database KM plotter [23].
Patients with higher PIP5K1A expression (n= 114)
suffered poorer DFS than patients with lower expression (n
= 115) (p= 0.048) in luminal subtype A [23] (Fig. 1d).
PIP5K1A mRNA expression was also associated with poor
DFS (p= 0.028) in triple-negative subtype from a patient
cohort in database KM plotter [23] (Fig. 1e). There was also
a clear trend that the triple-negative cancer patients from the
same cohort with higher AKT1 expression (n= 74) also had
poorer DFS as compared to those with lower levels (n= 38)
(p= 0.055), although only border significance was achieved
Table 1 Associations of PIP5K1α Expression and clinical-pathological
parameters in the whole series of breast cancer (BC)
Parameters PIP5K1α expression Significance
Negative/low no.
(%)
Positive/high
no. (%)
P value
Patients’ age (years)
≤50 173 (49.4) 177 (50.6) 0.409
>50 286 (50.4) 281 (49.6)
Menopausal status
Premenopausal 184 (50.0) 184 (50.0) 0.516
Postmenopausal 275 (50.1) 274 (49.9)
Tumor stage
Low-grade 294 (52.0) 271 (48.0) 0.024
High-grade 29 (35.8) 52 (64.2)
NPI
Good (<3.4) 143 (58.6) 101 (41.4) 0.002
Poor (≥5.41) 64 (41.0) 92 (59.0)
NPI Nottingham Prognostic Index
Table 2 Associations of PIP5K1α expression and clinical-pathological
parameters in luminal breast cancer
Parameters PIP5K1α expression Significance
Negative/low no.
(%)
Positive/high
no. (%)
P value
Patients’ age (years)
≤50 102 (51.8) 95 (48.2) 0.795
>50 207 (50.6) 202 (49.4)
Menopausal status
Premenopausal 114 (53.0) 101 (47.0) 0.255
Postmenopausal 195 (49.9) 196 (50.1)
Grade
Low-grade 66 (53.2) 58 (46.8) 0.031
High-grade 90 (43.5) 117 (56.5)
Tumor stage
Low-stage 200 (53.1) 177 (46.9) 0.01
High-stage 12 (28.6) 30 (71.4)
NPI
Good ( < 3.4) 128 (57.9) 93 (42.1) 0.004
Poor ( ≥ 5.41) 26 (36.1) 46 (63.9)
NPI Nottingham Prognostic Index
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(Fig. 1e) [23]. Gene amplifications in PIP5K1A were
observed in 20% (n= 164) of unselected cases (n= 817
cases) (TCGA database from cBioPortal [24–26]), 17% (n
= 102) of luminal ER+ subtype (n= 594), 24% (n= 29) of
HER-2 positive subtype (n= 120) and 29% (n= 24) of
triple-negative subtype (n= 82) (Fig. 1f). Thus, over-
expression of PIP5K1α in breast cancer is associated with
its gene amplification and poor prognosis in triple-negative
breast cancer patients.
PIP5K1α inhibitor ISA-2011B suppresses tumor
growth in a triple-negative breast cancer xenograft
mouse model
To study the involvement of PIP5K1α in breast cancer, we
tested the effect of PIP5K1α inhibitor ISA-2011B on breast
cancer cell growth. Here, we treated MCF-7 and MDA-MB-
231 cells with ISA-2011B at 10, 25, 50 and 100 μM doses
and found a dose-dependent inhibition (ISA-2011B at
25 μM as compared with vehicle control; for MCF-7 cells,
difference= 45%, 95% CI= 0.02, p < 0.001; for MDA-
MB-231 cells, difference= 19.5%, 95% CI= 0.0078, p=
0.036) (Fig. 2b). Further, the effect of ISA-2011B at 25 µM
was stronger on MCF-7 cells (p < 0.001) than on MDA-
MB-231 cells (p= 0.022) (Fig. 2a, b).
MDA-MB-231 cell line is a triple-negative breast cancer
model due to their lack of the expression of ER, HER-2 and
PR, but with constitutively high expression of pAKT. To
study the involvement of PIP5K1α in triple-negative breast
cancer and the treatment outcome of ISA-2011B in vivo, we
treated mice bearing MDA-MB-231 xenograft tumors of
50 mm3 in mean size with ISA-2011B, docetaxel or the
vehicle control via intraperitoneal injection. After 24 days
of treatment, we found ISA-2011B-treated tumors were 3-
fold smaller in size as compared with the vehicle control
group (mean tumor volume for vehicle-treated controls=
2160 mm3, mean tumor volume for ISA-2011B-treated=
600 mm3, difference= 1560 mm3; 95% CI= 0.15; p <
0.001, n= 6 per group) (Fig. 2c). Docetaxel as a positive
control also showed a significant inhibitory effect on growth
of MDA-MB-231 tumors (p < 0.001) (Fig. 2c).
Analysis of xenograft tumors removed from the mice
revealed that ISA-2011B-treated tumors had significantly
decreased proliferation rate as compared to the vehicle-
treated controls as determined using Ki-67 expression (p <
0.001, Fig. 2d). Remarkably, expression of pSer-473 AKT
was significantly decreased in ISA-2011B-treated tumors
compared with controls (p < 0.001). ISA-2011B-treated
tumors barely expressed cyclin D1, the downstream effec-
tor of AKT, and had significantly lower expression of
VEGF, VEGFR1 and VEGFR2, the angiogenic factors
associated with PI3K/AKT and invasiveness, as compared
with that of controls (for cyclin D1, p < 0.001; VEGF, p <
0.001; for VEGFR1, p < 0.001 and for VEGFR2, p < 0.001)
(Fig. 2e, f). Taken together, PIP5K1α inhibitor ISA-2011B
suppressed the growth and invasiveness of triple-negative
breast tumors, which is likely due to its inhibitory effect on
PIP5K1α and the downstream signals in the elevated PI3K/
AKT pathway.
PIP5K1α is a key regulator of AKT pathway in MDA-
MB-231 cells of triple-negative breast cancer model
To further elucidate the functional association of PIP5K1α
with pAKT and its downstream signaling pathway, we
overexpressed PIP5K1α in MDA-MB-231 cells by trans-
fection with pLPS-EGFP-PIP5K1α or pLPS-EGFP vector
as a control. PIP5K1α overexpression significantly
increased the level of pSer-473 AKT by 3.5 fold in MDA-
MB-231 cells as compared to those treated with the control
vector (p < 0.001) (Fig. 3a). Immunofluorescence analysis
showed the subcellular localization of PIP5K1α and pSer-
473 AKT in MDA-MB-231 cells (Fig. 3b). As a result of
elevated level of PIP5K1α, there was a significant increase
in proliferation rate, accompanied with the increased level
of cyclin D1 and cyclin A2 as compared with the controls
(for proliferation, p < 0.001; for cyclin A2, p= 0.007; for
cyclin D1, p= 0.011) (Fig. 3c, d). The migratory ability of
MDA-MB-231 cells overexpressing PIP5K1α was over
50% higher than that of the control (p < 0.001), which was
coincident with a dramatic induction of β-catenin, a key
marker of invasiveness (p= 0.004) (Fig. 3e, f). These
results suggest that PIP5K1α-induced activation of AKT
may contribute to increased growth and invasiveness of
triple-negative breast cancer.
Table 3 Statistical association of expression of PIP5K1α and clinical-
pathological parameters and the expression of PIK3CA in triple
negative BC
Parameters PIP5K1α expression Significance
Negative/low no.
(%)
Positive/high
no. (%)
P value
Patients’ age (years)
≤ 50 42 (48.8) 44 (51.2) 0.71
> 50 36 (46.8) 41 (53.2)
Menopausal Status
Premenopausal 42 (48.3) 45 (51.7) 0.013
Postmenopausal 36 (47.4) 40 (52.6)
Tumor size
≤2 cm 43 (58.1) 31 (41.9) 0.017
>2 cm 35 (39.3) 54 (60.7)
PIK3CA
Negative 14 (70.0) 6 (30.0) 0.037
Positive 49 (45.4) 59 (54.6)
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The underlying mechanisms by which ISA-2011B
inhibits growth and invasiveness of MDA-MB-231
cells
Next, we examined functional action and mechanisms of
ISA-2011B on MDA-MB-231 cells expressing elevated
level of PIP5K1α. ISA-2011B-treatment reduced the ratio
of MDA-MB-231 cells at S phase and G2/M phases,
respectively, as compared with the ratios in the control cells
(for S-phase, p= 0.011; for G2/M phases, p= 0.014) (Fig.
4a). Furthermore, a higher proportion of MDA-MB-231
cells treated with ISA-2011B underwent apoptosis as
compared with the control cells or cells treated with doc-
etaxel (the mean percentage of early apoptosis was 2% for
the control, 8.6% for ISA-1011B; Difference= 7%; 95%
CI= 0.53, p= 0.004) (Fig. 4b). ISA-2011B-treated cells
Fig. 2 The inhibitory effect of ISA-2011B on proliferation of breast
cancer cells and on growth of MDA-MB-231 xenograft tumors in
mice. a, b Dose-dependent inhibitions of ISA-2011B on the pro-
liferation of MCF-7 (a) and MDA-MB-231 cells (b) are shown. The
proliferation rates were determined using tetrazolium dye-based pro-
liferation (MTS) assay, and were shown in Y-axis by using the
absorbance relative to the controls. ISA-2011B at 25 µM, 50 µM and
100 µM was used. Mean absorbance of MCF-7 after treatment with
vehicle control and ISA-2011B at 25 μM respectively were 0.56 and
0.30 (difference= 45%; 95% CI= 0.02; p < 0.001) (a). Mean absor-
bance of MDA-MB-231 cells after treatment with vehicle control and
ISA-2011B at 25 μM were 0.11 and 0.09 respectively (difference=
19.5%; 95% CI= 0.0078; p= 0.036). Further, the effect of ISA-
2011B was stronger on MCF-7 cells at 25 µM (p < 0.001) than on
MDA-MB-231 (p= 0.022). Data is presented as average of three
independent experiments ( ± SD). p < 0.05, as indicated by “*”, p <
0.01, as indicated by “**”. c Growth of tumor xenografts treated with
vehicle (Ctrl), docetaxel (10 mg/kg), or ISA-2011B (40 mg/kg) every
second day. Treatment started on day 0 and ended on day 24 (n= 6
mice per group). Mean tumor volumes and upper 95% confidence
intervals are shown. **P < 0.01. Tumors from each group were col-
lected and weighed at the end of experiment. Each tumor from vehicle
control-treated group and ISA-2011B-treated group is shown (right
panel). d–f Representative microphotographs of immunohistochemical
analysis show the expression and cellular localization of Ki-67,
phosphorylated AKT, cyclin D1 (Cyc D1), VEGF, VEGFR1 and
VEGFR2 in vehicle-treated tumors vs. ISA-2011B-treated tumors as
shown in the left panels. Quantifications of proportion of Ki-67-
positive and staining intensities of various biomarkers are shown in the
right panels
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had significantly lower level of PIP5K1α (p < 0.001) and
pSer-473 AKT respectively (the average expression level of
pSer-473 AKT in the control and ISA-2011B-treated cells
was 0.78 and 0.60, respectively; difference= 23%, 95% CI
= 0.05, p < 0.001) (Fig. 4c). Unlike ISA-2011B, docetaxel
treatment made no difference on the expression of pSer-473
AKT (Fig. 4c). In addition, increased expression of p27 and
a coincident decreased expression of CDK1, two key factors
controlling cell cycle, were detected in cells treated with
ISA-2011B as compared with the control cells (for p27, p
= 0.001; for CDK1, p= 0.01) (Fig. 4d, e). This suggests
that ISA-2011B exerts its effect on DNA synthesis and
survival of cancer cells by blocking the specific pathway in
breast cancer.
Functional association of PIP5K1α, pAKT and cell
cycle regulators in MDA-MB-231 cells
Interestingly, similar to what was achieved using ISA-
2011B, siRNA-mediated knockdown of PIP5K1A reduced
PIP5K1α expression and pSer-473 AKT by over 50% as
compared with the si-scramble control (p= 0.008) (Fig. 5a).
Significantly lower level of cyclin A2 and cyclin D1 was
detected in MDA-MB-231 cells expressing si-PIP5K1α as
compared with the control cells (For cyclin A2, p= 0.038;
for cyclin D1, p= 0.003) (Fig. 5b). Thus, inhibition of
PIP5K1α via siRNA on the AKT pathway was equivalent to
ISA-2011B treatment in triple-negative breast cancer. This
confirmed the on-target effect of ISA-2011B in MDA-MB-
231 cells.
Regulation of PIP5K1α and its association with the
estrogen-mediated pathway in luminal breast
cancer
Constitutive activation of the PI3K/AKT pathway has been
found to be involved in cancer progression and drug
resistance to endocrine therapy in ER+ breast cancer [18].
We wanted to study if PIP5K1α could regulate the PI3K/
AKT pathway and whether PIP5K1α is associated with ER
signaling in ER+ breast cancer. To this end, we over-
expressed PIP5K1α in MCF-7 cells followed by the treat-
ment of 17β-Estradiol to stimulate ERα activation. PIP5K1α
overexpression increased pSer-473 AKT level by 100% as
compared to the control in the presence or absence of 17β-
Estradiol (average level in the control and pLPS-PIP5K1α-
treated cells were 0.50 and 1.02, respectively, difference=
0.52, 95% CI= 0.13; p= 0.01) (Fig. 6a). The additive
effects of PIP5K1α and 17β-Estradiol stimulation on upre-
gulation of phosphorylated AKT as compared with controls,
was also observed in MCF-7 cells (p= 0.016) (Fig. 6a).
Overexpression of PIP5K1α and co-stimulation of 17β-
Estradiol significantly increased expression level of cyclin
D1 and β-catenin by up to 90% as compared with the
control (for cyclin D1, p= 0.003; for β-catenin, p= 0.0002)
(Fig. 6b and c). VEGF receptors have been shown to act as
co-factors of estrogen receptor in ER+ MCF-7 cells [27,
28], suggesting that the VEGF signaling axis cooperates
with ER signaling. We observed that PIP5K1α formed a
protein complex with VEGFR2 as determined by an
immunoprecipitation assay and PIP5K1α was present in
both nucleus and cytoplasmic compartments in MCF-7 cells
(Fig. 6d). These results suggest that PIP5K1α acts mainly
on the PI3K/AKT pathway in cytoplasm and membrane,
while forms a complex with VEGFR2 in the nucleus to
cooperate with ERα on its target genes.
Inhibition of PIP5K1α by ISA-2011B sufficiently
blocked cyclin D1 activation and induced apoptosis
To test our hypothesis as mentioned above, we first inves-
tigated the effect of ISA-2011B treatment on PI3K/AKT
and ER signaling pathways. ISA-2011B treatment in MCF-
7 cells reduced pSer-473 AKT level by approximately 40%
and cyclin D1 level by over 90% as compared with the
control cells (for pSer-473 AKT, p= 0.007; for cyclin D1,
p < 0.0001) (Fig. 7a, b). In contrast, docetaxel treatment did
not alter the expression level of phosphorylated AKT and
cyclin D1 (Fig. 7a, b). In addition, ISA-2011B treatment
had no pronounced effect on apoptosis in non-malignant
MCF-10A breast cells as assessed by flow cytometry and
immunoblot analysis of activated PAPR, a pro-apoptotic
marker (Fig. 7c and Fig. 1 in Supplemental Figures and
Legends). ISA-2011B induced a high degree of apoptosis in
MCF-7 cells, which was similar to that induced by doc-
etaxel treatment, as measured by flow cytometry analysis
(early apoptosis control mean value= 2.5, ISA-2011B
mean value= 6.8; docetaxel mean value= 4.9; ISA-
2011B vs control p= 0.0005; for ISA-2011B vs Doc-
etaxel p= 0.02) (Fig. 7c). Immunofluorescent analysis of
apoptotic nuclei of the cells and immunoblot analysis of
activation of PARP further revealed that ISA-2011B
induced apoptosis, rather than necrosis in MCF-7 cells
(Supplemental Fig. 2).
Next, to investigate whether PIP5K1α may cooperate
with ERα to regulate its target genes, we performed assays
to test the outcome of ISA-2011B inhibition or PIP5K1A
knockdown on ERα-mediated estrogen signaling, using
luciferase (Luc) reporter under the control of an estrogen
responsive element (ERE) [29]. Treatment of MCF-7 cells
harboring a luciferase reporter containing 3 consensus
EREs, with 17β-Estradiol followed by the treatment with
ISA-2011B or DMSO vehicle control was performed. As
expected, 17β-Estradiol treatment induced ERE reporter
luciferase activity by 300% in MCF-7 cells as determined
by luciferase activity assays (p= 0.004) (Fig. 7d). In
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contrast, ISA-2011B treatment abrogated 17β-Estradiol-
induced transcriptional activity of the genes targeted by
ERα with 200% reduction (p= 0.009) (Fig. 7d). Similar to
ISA-2011B, PIP5K1A knockdown exerted equivalent inhi-
bition on 17β-Estradiol-triggered transcriptional activity of
ERα target genes (p= 0.027) (Fig. 7d). This suggests that
the induction of ERα target genes by 17β-Estradiol can be
suppressed by both ISA-2011B and the knockdown of
PIP5K1A. Next, we treated MCF-7 cells with 17β-Estradiol
and ISA-2011B individually or in combination for 1, 2 and
6 h, as the cell cycle of MCF-7 cells has been relatively
unperturbed prior to the longer treatment. We observed that
the 17β-Estradiol-induced upregulation of both mRNA and
protein expression of cyclin D1, a direct target of ERα, was
abrogated by ISA-2011B treatment readily at 2 h and up to
6 h (for cyclin D1 mRNA, p= 0.017 at 2 h and p= 0.01 at
6 h; for cyclin D1 protein, p= 0.004 at 2 h and p= 0.002 at
6 h) (Fig. 7e, f). In addition, knockdown ofPIP5K1A
resulted in a significant reduction of pSer-473 AKT by 50%
as compared to the control (Fig. 7g, difference= 0.31; 95%
CI= 0.06, p= 0.011). The level of cyclin D1 was sig-
nificantly lower in MCF-7 cells expressing siPIP5K1α than
Fig. 3 The effect of PIP5K1α
overexpression on proliferation
and migration in triple-negative
breast cancer MDA-MB-231
cells. a Effect of PIP5K1α
overexpression on the
expression of phosphorylated
AKT in MDA-MB-231 cells.
Immunoblots show the
expression of PIP5K1α and
phosphorylated AKT in MDA-
MB-231 cells transfected with
pLPS-EGFP control vector
(Ctrl) or pLPS-EGFP-PIP5K1α
(PIP5K1α). Quantification of the
immunoblots is shown. b
Representative immune-
fluorescent images show the
increased expression of
phosphorylated AKT (red) in
MDA-MB-231 cells transfected
with pLPS-EGFP-PIP5K1α
(PIP5K1α) as compared with the
controls. c The effect of
PIP5K1α overexpression on the
proliferation of MDA-MB-231
cells was determined using MTS
assay. d. Immunoblots show the
expression of cyclin A2 and
cyclin D1 in MDA-MB-231
cells overexpressing PIP5K1α or
control vector. eMigration assay
of MDA-MB-231 cells
overexpressing PIP5K1α or
control vector. f Immunoblots
show the expression of β-catenin
in MDA-MB-231 cells
overexpressing PIP5K1α or
control vector. SD ± values
indicate means of three
independent experiments. *p <
0.05 and **p < 0.01 are
indicated
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Fig. 4 Characterization of the effect of ISA-2011B on MDA-MB-231
cells and the underlying mechanisms. a Cell cycle distribution of
MDA-MB-231 cells treated with DMSO as vehicle control or ISA-
2011B at 25 µM. Representative FACS plots show the cell cycle status
in control MDA-MB-231 (Ctrl) or cells treated with ISA-2011B (ISA-
2011B) (left panel). ISA-2011B-treatment reduced the proportion of
MDA-MB-231 cells at S phase (mean control value= 26.31 and mean
ISA-2011B-treated value= 10.94%, p= 0.011) and G2/M phases
(mean control value= 14.025 and mean ISA-2011B-treated value=
8.47%, p= 0.014, as compared with the vehicle control). Data is
representative of three independent experiments are indicated (right
panel). b Representative FACS plots show the apoptosis status of
MDA-MB-231 cells treated with DMSO as vehicle control, docetaxel
or ISA-2011B using Annexin V-7AAD-based flow cytometry analysis
(left panel). Mean percentage of early apoptosis for control 2%, mean
percentage of early apoptosis for ISA-2011B was 8.6%; Difference=
7%; 95% CI= 0.53, p= 0.004, and the ability of ISA-2011B to induce
apoptosis in MDA-MB-231 cells was greater than that of docetaxel.
Data are representative of three independent experiments are indicated
(right panel). c, d. Immunoblot analysis shows the effect of ISA-
2011B on the expression of PIP5K1α, pAKT in the left panel (c) and
CDK1 and p27 in (d). SD ± values indicate means of three indepen-
dent experiments are indicated (right panel). e Representative micro-
photographs of the immuno-staining of the MDA-MB-231 cells that
were treated with vehicle control, docetaxel and ISA-2011B with
antibodies against PIP5K1α (green) and CDK1 (red), the merged
images are shown. SD ± values indicate means of three independent
experiments. *p < 0.05 and **p < 0.01 are indicated
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in the control cells (p= 0.006). These results showed that
the inhibitory effect on activation of AKT and expression of
cyclin D1 by PIP5K1α siRNA knockdown was equivalent
to ISA-2011B treatment. Further, depletion of PIP5K1α
also blocked 17β-Estradiol-induced cyclin D1 expression
(Fig. 7h). The ability of ISA-2011B to inhibit 17β-Estradiol-
ERα downstream gene activity such as cyclin D1 was found
to be similar to that of si-PIP5K1α. Taken together,
PIP5K1α inhibition, either by ISA-2011B or siRNA-
mediated knockdown, significantly abrogated the activity
of ERα and estrogen on inducing the target genes, sug-
gesting a potential of ISA-2011B for targeting ER+ breast
cancer with elevated PIP5K1α expression.
Discussion
Constitutively activated PI3K/AKT pathway resulted from
frequent PIK3CA gene mutations has been linked to dif-
ferent types of human breast cancers [18]. Previous studies
have shown PIP5K1α as an emerging cancer drug target and
a biomarker in prostate cancer, and a small molecule
PIP5K1α inhibitor with the ability to suppress tumor growth
in a castration-resistant prostate cancer xenograft mouse
model [15, 16]. The mechanistic studies have shown that
PIP5K1α acts upstream of the PI3K/AKT pathway as a lipid
kinase to produce PIP2, an important molecule to activate
AKT by PI3K in this signaling pathway [12, 30].
In this study, we show that PIP5K1α may be able to play a
significant role in breast cancer progression and metastasis.
Overexpression of PIP5K1α was associated with low DFS
and increased risk of distant metastasis in triple-negative
breast cancer. In addition, high level of PIP5K1α protein was
linked to luminal breast cancer subtype with high-grade and
poor prognosis. Furthermore, elevated level of PIP5K1A
mRNA was associated with poor DFS in luminal A subtype
of breast cancer. Our study was the first to show the clinical
significance of PIP5K1α in breast cancer subtypes, particu-
larly in the triple-negative breast cancer.
Our findings unravel important roles PIP5K1α may play
in proliferation, survival and metastasis of the triple-
negative breast cancer by using MDA-MB-231 cell line
and in vivo xenograft mouse model. Our results showed that
PIP5K1α overexpression significantly promoted prolifera-
tion and migratory ability of MDA-MB-231 cells, and such
effect in breast cancer was similar to what was found in
prostate cancer cell lines such as LNCaP and PC-3. We
further demonstrated that PIP5K1α exerts its effect on the
PI3K/AKT pathway, which in turn activates the down-
stream effectors such as cyclin A2, cyclin D1 and β-catenin.
As in prostate cancer, PIP5K1α plays such a role in breast
cancer via its kinase activity to produce PIP2, which acti-
vates the PI3K/AKT pathway.
Patients with triple-negative breast cancer often experi-
ence worst clinical outcome, and currently no effective
targeted therapies are available for treatment. In our current
study, we demonstrated that PIP5K1α inhibitor, ISA-
2011B, could induce apoptosis, with an effect comparable
to docetaxel. In addition, it significantly suppressed growth
of highly invasive MDA-MB-231 tumor in xenograft mice,
Fig. 5 The effect of PIP5K1α inhibition on AKT pathways in MDA-
MB-231 cells. PIP5K1A was silenced by transfecting MDA-MB-231
cells with PIP5K1A siRNA or scramble control (Ctrl). a, b Immuno-
blots for PIP5K1α, phosphorylated AKT, cyclin A2 and cyclin D1 in
MDA-MB-231 cells that were transfected with PIP5K1A siRNA or
scramble control are shown (left panel). (Mean pSer-473 AKT in
control was 0.45 and 0.23 in PIP5K1α knockdown cells, difference=
0.22; 95% CI= 0.11, p= 0.008) SD ± values indicate means of three
independent experiments. *p < 0.05 and **p < 0.01 are indicated (right
panel)
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which serves as a clinically relevant triple-negative breast
cancer model. Unlike docetaxel, which is a cytotoxic drug
targeting all proliferative cells, ISA-2011B inhibits tumor
growth and promotes apoptosis by blocking PI3K/AKT, a
key cancer survival and invasion pathway in MDA-MB-231
cells. In our studies, PIP5K1α overexpression remarkably
increased the level of phosphorylated AKT, while ISA-
2011B treatment or PIP5K1α knockdown significantly
decreased phosphorylated AKT, leading to down-regulation
of the downstream effectors. We further confirmed the
effect of ISA-2011B in vivo in MDA-MB-231 xenograft
tumors. ISA-2011B not only strongly inhibited tumor
growth, but also significantly lowered expression of phos-
phorylated AKT and its downstream effectors such as cyclin
D1, VEGF, VEGFR1 and VEGFR2. In striking contrast,
docetaxel treatment did not affect expression of AKT and its
effectors in the pathway. Thus, our study revealed the
potential of PIP5K1α as a druggable-target. In addition, it
shows the therapeutic potential of PIP5K1α inhibitor ISA-
2011B, as it specifically induces apoptosis and inhibits
metastasis by blocking the elevated PI3K/AKT pathway in
triple-negative breast cancer.
It has been reported that abnormal activation of PI3K/AKT
frequently occurs in a high proportion of ER+ breast cancer
patients, who often suffer from cancer recurrence and bone
metastasis [3]. In this study, we demonstrated that abnormally
high expression of the PIP5K1α/AKT pathway led to
increased survival and invasiveness of MCF-7 cancer cells.
The effect of ISA-2011B on MCF-7 cancer cells was medi-
ated through the PI3K/AKT pathway. Since the oncogenic
mutations of PIK3CA are found to trigger luminal ER+PR+
tumors in a transgenic mouse model [31], constitutively acti-
vated PI3K/AKT pathway may cooperate with ERα to pro-
mote invasiveness of ER+ breast cancer. Our study showed
that ISA-2011B blocked the activity of 17β-Estradiol to
induce expression of ERα target genes, leading to lower
expression level of cyclin D1 and CDK1 in MCF-7 cells. ISA-
2011B abrogated an early effect of 17β-Estradiol on cyclin D1
expression in MCF-7 cells at 2 h and up to 6 h. Although the
cell cycle in MCF-7 cells was relatively unperturbed prior to
the longer treatment, early ERα-target upregulation by 17β-
Estradiol was impaired after ISA-2011B treatment.
We found a protein–protein complex formation between
VEGFR2 and PIP5K1α. ISA-2011B or PIP5K1α knockdown
dramatically reduced expression of 17β-Estradiol-ERα
induced target genes such as the VEGF axis [27, 28]. Further,
the 17β-Estradiol-ERα complex regulates expression of target
gene by binding directly to estrogen response elements
(EREs) [32, 33]. Thus, in addition to its role as a lipid kinase
to produce PIP2, PIP5K1α may also act as a co-factor of
VEGFR2 to regulate the transcriptional activity of ERα-target
genes through VEGFR2. Thus, our study uncovers several
Fig. 6 Evaluation of the effect of PIP5K1α overexpression and its
functional link with estrogen signaling in MCF-7 cells. a Immunoblot
analysis shows the effect of PIP5K1α overexpression on pAKT
expression in MFC-7 cells in the presence or absence of 17β-Estradiol.
Antibodies against PIP5K1α and pSer-473 AKT were used. b, c
Immunoblots of cyclin D1 and β-catenin respectively in MCF-7 cells
transfected with PIP5K1α or control vector in the presence or absence
of 17β-Estradiol (left panels) (for cyclin D1, control transfected mean
= 0.62; PIP5K1α transfected mean= 1.07, difference= 0.45; 95% CI
= 0.08, p= 0.003; For β-catenin, control transfected mean= 0.51;
PIP5K1α transfected mean= 1.0, difference= 0.49; 95% CI= 0.03, p
= 0.0002). SD ± values indicate means of three independent experi-
ments. *p < 0.05 and **p < 0.01 are indicated (right panel). d MFC-7
cells were subjected to immunoprecipitation (IP) assay. Antibody
against PIP5K1α was used to pull down the immunocomplexes of
VEGFR2 in MCF-7 cells, and antibody to IgG was used as a negative
control. Conversely, antibody against VEGFR2 was also used to pull
down the immunocomplexes of PIP5K1α in MCF-7 cells, and anti-
body to IgG was used as a negative control. Antibodies against
VEGFR2 or PIP5K1α were used for immunoblot analysis (IB). The
equal amount of total lysates, cytoplasmic (C) and nuclear (N) frac-
tions were used as input control for immunoblot analysis of the
immunoprecipitated protein lysates. Antibodies against PIP5K1α or
VEGFR2 were used
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unrecognized inter-links among PIP5K1α, PI3K/AKT, ER
and cyclin D1 in ER+ breast cancer. Furthermore, we showed
that ISA-2011B did not exert toxic effect on a well-
characterized normal breast cell line MCF-10A in striking
contrast to MCF-7 cancer cells. Thus, ISA-2011B has an on-
target inhibitory effect on breast cancer cells. Our study
demonstrated the potential of developing ISA-2011B as a new
targeted therapy to treat triple-negative and ER+ breast can-
cers with metastatic potential.
Materials and methods
Sources of tissue specimens, TMAs and mRNA
expression data
TMAs containing a well-characterized annotated series of
unselected primary breast cancer from 913 patients were
constructed as described before [22] (Tables 1, 2 and 3).
Distant metastasis-free survival or DFS were analyzed. The
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detailed clinico-pathological data and treatment regimens
were described in previous reports [34, 35]. For evaluation
of tumor tissues on TMAs, all of the samples were coded
and scored by pathologists and scientists working at dif-
ferent institutions. Immunohistochemical analysis was per-
formed as previously descried [16]. The second (n= 112)
and third (n= 229) cohorts used came from the
Kaplan–Meier plotter (KM Plotter) (www.kmplot.com)
[23], and the fourth cohort (n= 817) was obtained from
TCGA in the cBioPortal database [24–26]. The study was
approved by the Nottingham Research Ethics Committee
and the Ethics Committee at Lund University and Region
Skåne in Sweden. The guidelines in Helsinki Declaration of
Human Rights were strictly followed during the study.
Cell culture and treatments
Breast cancer cell line MDA-MB-231 and MCF-7 were
purchased from American Type Culture Collection (Man-
assas, VA) and cultured in RPMI-1640 medium with phenol
red, which was supplemented with 10% fetal bovine serum
(FBS), 1% penicillin-streptomycin-neomycin and 2 mM L-
Glutamine (PAA Laboratories, GmbH). Before treatment,
the cells were cultured in phenol red-free RPMI-1640
medium supplemented with 10% charcoal-stripped serum
for 24 h. ISA-2011B at 20 µM or 50 µM, Docetaxel at
10 nM, solvent of 0.1% DMSO (V/V), or 17β-Estradiol at
10 nM were used for the treatment.
PIP5K1α transfection and siRNA knockdown
Full-length cDNA of human PIP5K1α (pLPS-PIP5K1α) or
control vector (pLPS-EGFP) were constructed and tran-
siently transfected using a transfection reagent Lipofecta-
mine® 2000 (Life Technologies, Paisley, UK) following the
manufacturer’s instructions [16]. In PIP5K1α knockdown
experiment, breast cancer cells were treated with PIP5K1A-
siRNA or negative control siRNA (VWR International Inc.)
respectively by using TransIT-TKO® kit according to the
manufacturer’s instructions (Mirus Bio LCC). Various
analyses were performed on the cells at the time points of
24, 48 and 72 h post-transfection.
Establishment of MDA-MB-231 xenograft mouse
model and treatment
All in vivo experiments were performed after approval by
the local ethics committee at Lund University. MDA-MB-
231 cells (4 × 106) were implanted subcutaneously into the
female BALB/c nude mice at the age of 8–12 weeks. After
the mean tumor volumes reached 50 mm3, the mice were
randomly assigned into three different groups (6 mice/
group). The three groups of mice were treated with vehicle
(control), docetaxel (10 mg/kg) and ISA-2011B (40 mg/kg),
respectively, by intraperitoneal injection once every other
day. The body weight and tumor diameters were measured
every other day. The tumor volume was calculated with
tumor diameters using the equation (a × b2/2). After the
treatment was completed, the mice were sacrificed and the
tumors were collected for analysis.
Immunohistochemical analysis
Breast cancer TMA and paraffin-embedded tumor tissues
from the xenograft study were stained using various anti-
bodies as previously described [16]. The slides were stained
using a semiautomatic staining instrument (Ventana ES)
and then scanned with a high-resolution scanner (Scansco-
peCS, Aperio). The stained TMAs were scored with semi-
quantitative Histochemical score (H-score), which was
determined by multiplying the percentage of stained inva-
sive tumor cells (minimum 0 and maximum 100) and the
staining intensity (0 was negative, 1 was weak, 2 was
moderate and 3 was strong staining). All of the specimens
were blindly scored using a coding system.
Immunoblot, immunoprecipitation and subcellular
fractionation assays
Immunoblot, immunoprecipitation and subcellular fractio-
nation were performed as described previously [15]. For
immunoprecipitation assay, PIP5K1α or VEGFR2 antibody
Fig. 7 Evaluation of the effect of ISA-2011B and inhibition of
PIP5K1α by siRNA-mediated knockdown on MCF-7 cells. a, b
Immunoblot analysis of expression of phosphorylated AKT and cyclin
D1 in MCF-7 cells treated with DMSO (-), docetaxel and ISA-2011B
respectively (left panel). SD ± values indicate means of three inde-
pendent experiments are indicated (right panel). c The effect of ISA-
2011B on induction of cell death in MCF-10A cells. The percentages
of Annexin V+ 7AAD- (early apoptosis) and Annexin V+7AAD
+(late apoptosis) is indicated. DMSO is used as vehicle control. The
effect of ISA-2011B and docetaxel on induction of cell death in MCF-
7 was determined using Annexin V-7AAD-based flow cytometry
analysis. Representative FACS plots show the early (green) or late
apoptosis status (orange) of MCF-7 cells that were treated with DMSO
as vehicle control, docetaxel or ISA-2011B (left panel). SD ± values
indicate means of three independent experiments are indicated (right
panel). d Effect of ISA-2011B treatment or si-RNA mediated knock-
down of PIP5K1α on the activity of estrogen responsive gene in the
presence of absence of 17β-Estradiol (E2) was assessed using luci-
ferase assay. e Quantification of RT-PCR of cyclin D1, normalized
with GAPDH, in MCF-7 cells after treatment with DMSO (-), E2, ISA-
2011B and combination of E2 and ISA-2011B for 1 h, 2 h and 6 h. f
Western blot analysis of Cyclin D1 and GAPDH in MCF-7 cells after
treatment with DMSO (-), 17β-Estradiol, ISA-2011B and combination
of E2 and ISA-2011B for 1 h, 2 h and 6 h. Below panel indicates the
semi-quantification of data. g, h The effect of siRNA-mediated
knockdown of PIP5K1α on the expression of pAKT and cyclin D1 in
presence or absence of E2. SD ± values indicate means of three inde-
pendent experiments. *p < 0.05 and **p < 0.01 are indicated
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was used to pull down the immune-complex, with an IgG
antibody (BD Biosciences, San Jose, CA, USA) used as
negative control. Various antibodies were used in immu-
noblot as shown below: PIP5K1α (Proteintech Inc. and Cell
Signaling Technology), Phospho-S473 AKT, CDK1, cyclin
D1 (Cell Signaling Technology and Santa Cruz Bio-
technology), VEGF, VEGFR1, VEGFR2, p27, Cyclin A2,
anti-GAPDH (Santa Cruz Biotechnology), ERα (Biosite),
Ki-67 (DAKO), MMP-9 (Abcam), anti β-Actin (MP Bio-
chemicals), cyclin E (Upstate Inc.). Immunoblot analysis
was performed and semi-quantified using ImageJ Image
Analysis Software (NIH, MD, USA).
Immunofluorescence assasy
Breast cancer cells were first seeded on glass coverslips and
then treated with different agents for 48 h. Image-iT™ FX
signal enhancer (Molecular Probes, Inc) was used for
blocking nonspecific background staining. Phospho-473
AKT, PIP5K1α and VEGFR2 antibodies were used as
primary antibodies. Donkey anti-rabbit conjugated to Rho-
damine antibody (Chemicon/Millipore) or donkey anti-goat
conjugated to FITC antibody at 1:200 dilution, and goat
anti-rabbit conjugated to Alexa Fluor 488 at 1:500 dilution
(Invitrogen) were used as secondary antibodies. 4′,6-Dia-
midino-2-phenylindole (SERVA Electrophoresis GmbH)
was used to counterstain the cells for visualization of cell
nuclei. The images were viewed and taken using Olympus
AX70 fluorescent microscope (Nikon DS-U1).
Flow cytometry (FACS)-based apoptosis and cell
cycle analysis
Flow cytometry (FACS)-based assays were performed on
cells treated with ISA-2011B to analyze cell cycle and
apoptosis. Propidium iodide (Sigma-Aldrich) staining was
used during flow cytometry for cell cycle analysis (CyAn
ADP, Beckman Coulter). For apoptosis assay, FITC or PE-
conjugated Annexin V and 7-AAD staining was performed
according to the manufacturer’s protocol (BD Biosciences).
Data analysis was performed with FCS Express (DeNovo
Software), FlowJo (Tree Star Inc., OR, USA) or CytExpert
(Beckman Coulter) software.
RNA purification and PCR
mRNA was purified from MCF-7 cells after treatment as
previously described [36]. The following primers were used
in PCR: CCND1 forward: 5′-ATG CCA ACC TCC TCA
ACG AC-3′, reverse: 5′-TCT GTT CCT CGC AGA CCT
CC-3′. GAPDH forward: 5′-AAC AGC GAC ACC CAC
TCC TC-3′, reverse: 5′-GGA GGG GAG ATT CAG TGT
GGT-3′. PCR was performed under the following cycling
condition: DNA denaturation for 5 min at 95 °C, 18 cycles
of 30 s annealing at 65.5 °C and 30 s extension at 72 °C, and
final 10 min extension at 70 °C. Semi-quantification was
performed using ImageJ Image Analysis Software (USA).
Luciferase assay
MCF-7-ERE-luc cells were cultured in phenol red-free 10%
charcoal stripped medium in the presence of various agents
alone or in combination. 10 nM 17β-Estradiol, alone or in
combination with either 50 µM ISA-2011B or 0.1% DMSO
(V/V) solvent, were used for treatment. After the treatment, the
cells were first lysed and then measured for Firefly Luciferase
and Renilla Luciferase activities, which were tested by using
the dual luciferase reporter assay kit (Promega). The effect of
ISA-2011B or si-PIP5K1α on transcriptional activity of the
ER target genes containing ERE in MCF-7-ERE-luc cells was
measured with Infinite® M200 multimode microplate reader
equipped with a dual injector (Tecan Sunrise™).
Cell migration assay
Cell migration assay was performed in Boyden trans-well
chambers (8 μm) following the manufacturer’s instructions
(BD Biosciences). The cells were seeded into the upper
chamber, while 20% of FBS as chemo-attractant was
applied in the lower chamber. After 20 h of incubation, the
cells that did not migrate and remained in the upper
chamber were removed with cotton swabs, and the cells
migrated away were first fixed with 4% paraformaldehyde,
and then stained with crystal violet dye. The stained cells
were quantified under microscope.
Statistical analysis
Tukey-test, T-test, Kruskal Wallis/ANOVA test and Spearman
Rank Correlation Test were performed. The immunohis-
tochemistry H-scores were log-transformed to compensate for
the non-normal distribution of H score data. The mean value is
the average value of all samples. The standard deviation (SD)
is an indication of variability of all samples. The precision of
the sample mean is indicated by standard error. The con-
fidence level is expressed using 95% confidence interval (CI).
All of the statistical testes were two-sided, and p < 0.05 was
considered to be statistical significant. For all in vitro experi-
ments, at least three independent experiments were conducted.
All quantification data presented in the studies was average of
at least three independent experiments. Statistical software and
Social Science software (SPSS, version 21, Chicago) were
used in statistical analysis. Detailed statistical calculations
were described in relevant figure text.
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